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echocardiography. The aim of this study was to validate RaVL as an index of
left ventricular hypertrophy (LVH) using cardiac MRI (CMR) in different
conditions.
Design and methods: In a cohort of 501 patients, CMR and ECG were
performed within a median-period of 5 days. The CMR LVH cut-offs used
were 83g/m2 in men and 67g/m2 in women.
Results: In mutivariable analysis (adjusted for age, left ventricular volume,
blood pressure, age and gender), RaVL was correlated with LVMI in the
whole cohort and also in patients with or without myocardial infarction (MI):
β=0.037, p<0.001; β=0.053, p<0.001; β=0.039, p=0.010, respectively. In the
whole cohort, area under ROC curve (AUC) was 0.729 (specificity 98.3%,
sensitivity 19.6%, optimal cut-off 1.1mV, 75.8% correctly classified). In the
subgroup without MI (N=300), an optimal value of 1.0mV classified correctly
80.7% of patients (AUC 0.781, specificity 95.5%, sensitivity 35.5%). In the
subgroup with MI (N=201), RaVL had a lower diagnostic performance (AUC
0.673, specificity 97.7%, sensitivity 13.2%, optimal threshold 1.1mV). We
observed the same diagnostic performance of RaVL in women and in men
without MI (optimal threshold 1.0mV, AUC 0.788 and 0.778 respectively).
The diagnostic value of RaVL was lower in patients with left bundle branch
block (BBB) or left deviation axis in comparison with those having right BBB
(optimal threshold 1.0mV for all, AUC 0.556, 0.753 and 0.933 respectively).
Conclusion: Using the gold standard to assess LVMI, our results demon-
strated thar RaVL is a good index of LVH with a threshold around 1.0mV
independently of various clinical conditions.
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Objective: Hypertension is another common condition in older subjects,
representing the most common morbid condition after osteoarthritis (Psaty
et al., 2001). Hypertension represents a major risk factor for cardiovascular
disease, the major source of morbidity among the over 65 population
(ISTAT, 2005). In such a context, the aims of the present study were to
investigate whether hypertension was associated independently with phys-
ical disability.
Design and Methods: A cross-sectional survey was conducted, covering a
sample of 598 subjects (202 male , 396 female, mean aged 72,3 years) aged
65 years and over. The study approved by ethics Committee and supported by
OMS and FNUAP. Information was gathered by home-based personal inter-
view using a structured questionnaire. We assessed their disability status,
sociodemographic informations and health behaviours. Disability was
recorded on three levels scale: (intense, moderate and no disability) Statistical
analysis was performed with SPSS and the significance was accepted at the p
< 0.05 level. Multiple logistic regression models were used to obtain the inde-
pendent variables associated with hypertension.
Results: The prevalence of hypertension was 52% (n=311), more frequent
for female population (55% vs 45% for male). The prevalence of disability
was 34.6%, only 10% have intense disability. Those with hypertension had
higher Body Mass Index, waist circumference and diabetes. Regarding dis-
ability, the individuals who presented the highest prevalence of hypertension
were more dependent. Multiple logistic regression revealed that the following
were significantly independent factors of hypertension: Disability (OR = 1.6).
Diabetes mellitus (OR = 2.36]).and a higher BMI (OR = 2.36).
Conclusions: We conclude that hypertension is associated not only to car-
diovascular factors (Diabetes obesity) but also with higher functional dis-
ability. Older subjects are exposed at significantly higher likelihood of
physical disability. Public health strategies to prevention hypertension in
elderly may protect them also against disability.
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Background: The sixth Joint National Committee (JNC-VI) classification
system of blood pressure emphasizes both systolic blood pressure (SBP) and
diastolic blood pressure (DBP) for cardiovascular disease risk assessment.
Pulse pressure (PP) = [SBP-DBP], may also be a valuable risk assessment
tool.
Objectives: In this study, we examined the association of cardiovascular
events with arterial pulse pressure in elderly as well as their correlations
within diabetes. 
Patients & methods: A Population based survey supported by WHO and
FNUAP, was undertaken in 2008-2009 to investigate health behaviours and
health status of elderly living in their home in Monastir. This study was car-
ried out in a representative sample of elderly aged more than 65 years. Stan-
dardized techniques were used for blood pressure (BP). Hypertension was
defined as BP more than 140/90 mmHg. Diabetes was defined as known dia-
betics. Regression analyses were used to examine the relationships among
pulse pressure age, diabetes and cardiovascular events (myocardial infarction,
arteritis and stroke).This project was approved by the research Ethics
Committee, CHU F Bourguiba, university of Monastir
Results: The study included 598 participants (396 women and 202 men)
who were aged ≥65 years. The prevalence of hypertension and diabetes was
respectively 52% (n=311) and 27,4% (n= 164). Pulse pressure was more than
65 mmHg for 132 subjects (22%), only 43 subjects without a history of hyper-
tension. The mean of PP is significantly high in hypertensive elderly (52.3 vs
58.4 mmHg), with cardiovascular events (55 vs 58 mmHg), diabetic subjects
(53 vs 58 mmHg), with comorbidity (54 vs 58 mmHg) and polymedication
(52 vs 57 mmHg). Using pulse pressure (high PP ≥65 mmHg) as dependent
variable, the multiple regression analysis reveals the independent influence of
diabetes and cardiovascular events on PP.
Conclusion: This study has confirmed that subjects with the widest PP
have the greatest risk of cardiovascular events. Elderly diabetic patients have
a higher PP than non diabetic elderly. These hemodynamic changes may
contribute to the increase risk of cardiovascular disease associated with
diabetes.
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Introduction and objectives: Primary hyperaldosteronism is the most
common cause of secondary hypertension. Elevated aldosterone levels cause
heart damage and increase cardiovascular morbidity and mortality. Early diag-
nosis could change the course of this entity. The objective of this report was
to study the clinical characteristics, cardiac damage and cardiovascular risk
associated with primary hyperaldosteronism in Algerian cohort.
Methods: We studied 149 patients with this diagnosis. We analyzed the
reason for etiological investigation, and the routinely performed tests,
including echocardiography. We used a cohort of 590 essential hypertensive
patients followed in our hospital for comparison.
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Results: Compared with essential hypertensive patients, those with hyper-
aldosteronism were younger (56.9 [11.7] years vs 60 [14.4] years; P<.001),
had higher blood pressure prior to the etiological diagnosis (156 [23.2] mmHg
vs 136 [20.6] mmHg), more frequently had a family history of early cardio-
vascular disease (26.7% vs 2.3%; P<.001), and had a higher prevalence of
concentric left ventricular hypertrophy (72% vs 25.4%) and higher cardiovas-
cular risk. Specific treatment resulted in optimal control of systolic and dia-
stolic blood pressures (from 150.7 [23.0] mmHg and 86.15 [14.07] mmHg to
12.69 [15.3] mmHg and 76.34 [9.7] mmHg, respectively). We suspected the
presence of hyperaldosteronism because of resistant hypertension (38.6%),
hypokalemia (39.7%), and hypertensive crises (12.7%). Only 4.3% of these
patients had been referred from primary care with a suspected diagnosis of
hyperaldosteronism.
Conclusions: Hyperaldosteronism should be suspected in cases of resistant
hypertension, hypokalemia and hypertensive crises. The diagnosis of hyperal-
dosteronism allows better blood pressure control. The most prevalent target
organ damage is left ventricular hypertrophy.
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Despite a well-recognized clinical benefit of the 2nd generation tyrosine
kinase inhibitor nilotinib in patients with imatinib-resistant/-intolerant or
newly diagnosed chronic myeloid leukemia, recent evidence suggests that
nilotinib has a propensity to increase the risk of occlusive arterial events, espe-
cially in patients with pre-existing cardiovascular risk factors. Given the key
role of lipids in cardiovascular diseases, we studied the plasma lipid profile
and global cardiovascular risk prior to and during nilotinib therapy in a series
of 27 patients in the setting of an observationalsingle-center study. Data from
a minimum 1-year follow-up showed that nilotinib significantly increased
total, low and highdensity lipoprotein cholesterol within 3 months. Conse-
quently, the proportion of patients with non-optimal low density lipoprotein
cholesterol increased from 48.1% to 88.9% by 12 months, leading to choles-
terol-lowering drug intervention in 22.2% of patients. The proportion of
patients with low levels of high density lipoprotein cholesterol decreased from
40.7% to 7.4% by 12 months. In contrast, a significant decrease in triglycer-
ides was observed. Global cardiovascular risk worsened in 11.1% of patients
due to diabetes or occlusive arterial events. Whether hypercholesterolemia
was the main driver of occlusive arterial events was uncertain: a longer
follow-up is necessary to ask whether nilotinib-induced hypercholesterolemia
increaseslong-term risk of atherosclerotic diseases. Nevertheless, given
keyatherogenicproperties of low density lipoprotein cholesterol, we conclude
that when prescribing nilotinib, commitment to detect lipid disordersat base-
line and during follow-up is mandatory given their frequency, requirement
for lifestyle or drug intervention and potential for long-term cardiovascular
complications. 
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Background: Nilotinib is approved for use in pts with CML after failure
of imatinib and in newly diagnosed CP-CML. However, several studies
report a nilotinib-associated risk of AOE (arterial occlusive event), espe-
cially in pts with preexisting risk factors for CVD. In this study, we aimed
at determining whether CVD risk estimation using the 2012 ESC classifica-
tion could be useful to identify patients at high risk of AOE during nilotinib
therapy.
Methods: Pts (n=75) treated with nilotinib upfront or after failure of prior
TKI at our institution were included provided that baseline CVD status could
be retrospectively collected. Patients were categorized into 2 groups according
to ESC 2012 classification: low/moderate (L/M) and high/very high (H/VH)
CVD risk.
Results: At nilotinib initiation, median age was 51 years (19-76), 41 pts
(54.7%) were males. At baseline, medical history revealed H/VH risk category
in 15 pts (20%) including established CVD in 6 pts (8%) (all diagnosed before
CML), DM (diabete melitus) in 10 pts (13.3%), severe AH (arterial hyperten-
sion) in 1 pt (1.3%), familial dyslipidemia in 1 pt (1.3%) and a SCORE ≥5%
in 2 pts (2.6%). 
AOE occurred in 12 pts with myocardial infarction (MI) or coronary heart
disease (CHD) (n=3), cerebrovascular events (CeVD) (n=3) and peripheral
artery disease (PAD) (n=6). Cumulative incidence of AOE by 48 months was
72.22% (95% CI: 47.46-100) in the H/VH group and only 12.13% (95% CI:
4.32-34.08) in the L/M group. Log Rank comparison of Kaplan Meier analysis
of 48-month survival without AOE showed a significant difference between
the 2 groups (27.78% (95% CI: 0-58.9) versus 84.38% (95% CI: 67.04-100)
p=0.0001). Sensitivity of the ESC classification in nilotinib-treated patients
was 67% and specificity 89%. 
Conclusions: In our retrospective study, CVD risk estimation
according to the 2012 ESC classification reveals that pts who belong to the
H/VH risk group at baseline are at very high risk of AOE during nilotinib
therapy. In this context, CVD risk should be reassessed throughout therapy
and risk factors should be tightly controlled according to current guide-
lines. 
0270
Arterial involvement in Behcet's disease: a series of 20 cases
Tounsi Ahmed (1), Abid Leila (1), Triki Feten (1), Elaoud Sahar (2),
Frikha Feten (2), Hentati Mourad (1), Bahloul Zouhir (2), Kammoun
Samir (1)
(1) CHU Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) CHU Hédi Cha-
ker, Médecine interne, Sfax, Tunisie
Background: While venous manifestations are frequent and have been
reported in many publications, data regarding arterial lesions in patients with
Behçet's disease (BD) are rare and often isolated.
Aim: We report our experience with a rare and interesting subset of BD
patients with arterial involvement
Methods: From 1998 to 2013, 20 cases of arterial involvement were found
amongst BD patients in the department of internal medicine of Hedi Chaker
Hospital. All these patients fulfilled International Study Group criteria for BD.
Results: The mean age when arterial involvement manifested was diag-
nosed was 32.9±9.9 years, and 18 of the patients were male. Combination of
venous and arterial manifestations occurred in 10 patients The artery most
often affected is the pulmonary arteries (11 cases) followed by the aorta, the
femoral arteries (5 cases) and the coronary arteries (4 cases). The arterial
disease was the presenting symptom of Behcet's disease in 13 cases. Arterial
lesions included arterial thromboses (45%), aneurysms (30%), stenosis
(20%) and Coronaritis (5%). 15 patients underwent corticosteroids and
4 patients underwent immunosuppressive therapy. Three patients were suc-
cessfully operated for aneurysms. After a median follow-up of 66.9± 54.4
months, 3 patients had died, in 2 cases directly related to cardiac involve-
ment.
Conclusion: Arterial findings are not uncommon in BD. Assessment of the
cardiovascular system is advised in patients with BD even if there is no cli-
nically apparent cardiovascular disease. 
